Prostate cancer is the most common noncutaneous malignancy in the United States and is responsible for many male deaths. The development of prostate carcinogenesis is initially androgen-dependent. However, the progression of castration-resistant prostate cancer (CRPC) following androgen deprivation therapy is a major clinical problem. Although enzalutamide and abiraterone have been approved for CRPC hormone therapy,